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https://doi.org/10.1016/j.celrep.2021.109969SUMMARYMicroRNAs (miRNAs) have emerged as critical regulators of cell fate in the CD8+ T cell response to infection.
Although there are several examples of miRNAs acting on effector CD8+ T cells after infection, it is unclear
whether differential expression of one or more miRNAs in the naive state is consequential in altering their
long-term trajectory. To answer this question, we examine the role of miR-29 in neonatal and adult CD8+
T cells, which express different amounts of miR-29 only prior to infection and adopt profoundly different fates
after immune challenge. We find that manipulation of miR-29 expression in the naive state is sufficient for
age-adjusting the phenotype and function of CD8+ T cells, including their regulatory landscapes and long-
term differentiation trajectories after infection. Thus, miR-29 acts as a developmental switch by controlling
the balance between a rapid effector response in neonates and the generation of long-livedmemory in adults.INTRODUCTION
MicroRNAs (miRNAs) are small noncoding RNAs which regulate
much of the transcriptome in mammals. Mammalian genomes
contain hundreds of conservedmiRNAs; cumulatively, the scope
of miRNA-mediated regulation indicates that most gene regula-
tory pathways incorporate miRNAs (Bartel, 2009). Canonically,
miRNAs recognize their target mRNAs by base pairing between
the 50 region of the miRNA, a 6–8 nucleotide sequence called the
seed, and a cognate target site in the 30 untranslated region.
Effective targeting results predominantly in mRNA destabiliza-
tion (Bartel, 2018). Because targeting is specified by the seed,
miRNAs sharing the same seed are grouped into families, with in-
dividual members often serving redundant functions due to their
common target repertoire (Bartel, 2009).
In the immune system, miRNAs contribute to a multitude of
cellular functions (O’Connell et al., 2010). In T cells, miRNAs
play an integral role in thymic maturation (Podshivalova and Sal-
omon, 2013), homeostasis, survival, activation (Bronevetsky
et al., 2013; Zhang and Bevan, 2010; Dooley et al., 2013),
effector and memory cell differentiation (Kroesen et al., 2015;
Liang et al., 2015; Smith et al., 2015), and establishment of acti-
vation thresholds (Liston et al., 2012). One miRNA, miR-29, has
been studied in CD4+ T cells (Wells, Pobezinskaya and Pobezin-
sky, 2020) but minimally in CD8+ T cells. In CD4+ T cells, miR-29C
This is an open access article under the CC BY-Nregulates Notch (Chandiran et al., 2018), T-box transcription fac-
tors, and inflammatory cytokine production (Steiner et al., 2011,
Ma et al., 2011) and also controls polarization after infection
(Chandiran et al., 2018).
The major functions of CD8+ T cells are to secrete effector
molecules that kill intracellular pathogens, and cytokines that
mobilize immune cells to respond to pathogens (Butz and Bevan,
1998; Whitmire et al., 2005). Neonatal CD8+ T cells exhibit pro-
found functional differences to their adult counterparts (Rudd,
2020), a phenomenon that extends to other immune cells (Yu
et al., 2018; Basha, Surendran and Pichichero, 2014; Philbin
and Levy, 2009). Neonatal CD8+ T cells are derived from fetal
liver rather than bone marrow stem cells, have different meta-
bolic programs, increased secretion of cytolytic molecules,
and have a higher proliferative and activation capacity (Smith
et al., 2018; Wang et al., 2016; Tabilas et al., 2019; Reynaldi
et al., 2016). Moreover, neonatal CD8+ T cells have a propensity
to become terminally differentiated at the cost of forming immu-
nological memory (Smith et al., 2014). Thus, identifying the reg-
ulatory programs that differentiate adult and neonatal CD8+
T cells remains a key question for understanding the immune
system.
Multiple miRNAs exhibit dynamic expression during thymic
development of CD8+ T cells, and play a role in balancing mem-
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OPEN ACCESS(Zhang et al., 2018; Muljo et al., 2005; Wu et al., 2007; Wu et al.,
2012). In adult mouse naive CD8+ T cells, miR-29a is among the
most highly expressed miRNAs, and is the most highly ex-
pressed member of the miR-29 family (miR-29a, b-1, b-2 and
c) (Wissink et al., 2015). Moreover, miR-29 is developmentally
regulated; miR-29 expression is high in adult naive CD8+
T cells, in both mice and humans, but lower in neonatal cells
(Wissink et al., 2015). Importantly, adult and neonatal naive
CD8+ T cell transcriptomes exhibit reciprocal changes in expres-
sion of likely targets ofmiR-29 (Wissink et al., 2015), implying that
miR-29 specifies regulatory differences in an age-related
fashion, with a set of targets expressed at higher levels in
neonatal CD8+ T cells concomitant with low miR-29 levels (Wis-
sink et al., 2015). Possible miR-29 targets include Tbet, Eomes,
Dnmt3a and IFNg, regulators that define CD8+ T cell fate (Wis-
sink et al., 2015; Ma et al., 2011; Steiner et al., 2011). Thus, we
hypothesized that miR-29 acts as a developmental switch prior
to infection that specifies alternative gene regulatory programs
in naive cells, which delineate adult and neonatal CD8+ T cell
fates by controlling the balance between the effector response,
characteristic of neonatal cells, and the generation of memory
cells, observed in adults (Wissink et al., 2015).
A number of studies have linked the fate of CD8+ T cells to spe-
cific miRNAs that arise after infection. For example, miR-17-92 is
upregulated in effector cells and drives proliferation by enhancing
PI3K-Akt-mTOR signaling (Wu et al., 2012), while miR-155
expression supports CD8+ T cell expansion by blunting the anti-
proliferative effect of type I interferons after infection (Gracias
et al., 2013). Furthermore, miR-146a is upregulated in effector
cells and facilitates resolutionof theCD8+Tcell response to infec-
tion (Yang et al., 2012). Collectively, these reports have led to a
prevailing notion that the CD8+ T cell trajectory during infection
is governed by the expression of miRNAs that are abundant in
effector cells. Thus, an important unansweredquestion iswhether
differentialmiRNAexpression in naiveCD8+Tcells is consequen-
tial to downstream function.
Here, we examined the significance and role of miR-29 in pri-
mary human and mouse naive CD8+ T cells. Our results demon-
strate that miR-29 expression in adult naive cells specifies a
gene regulatory program that promotes immune memory. In
contrast, low miR-29 expression in neonatal CD8+ T cells im-
pairs a robust memory response. Taken together, this studyFigure 1. miR-29 is required for normal CD8+ T cell function
(A) PrimeFlow assay of miR-29a (y axis - geometric mean fluorescence intensity, g
and true naive and virtual memory subsets (middle and bottom, respectively) s
plotting ± SD of 2 experiments with 3 mice per group per experiment, ***p % 0.0
(B) (Top) Contour plots of TN and VM splenic CD8+ T cells from WT and KO mic
(C) Kinetics of WT and KO CD8+ T cells throughout VACV-gB primary infection (
periments with 8-10 mice per group per experiment; 2-WAY ANOVA, *p % 0.05,
(D) Representative contour plots (top) ofWT and KOSLEC andMPECCD8+ T cells
6-7 mice per group per experiment; 2-WAY ANOVA, ****p % 0.0001.
(E) Histograms of IFNg, GZMB and TNFa after peptide restimulation of CD8+ T c
(F) Pathogen burden quantification of Listeria-gB colony forming units (y axis) at 3
mice per group per experiment; 2-WAY ANOVA, *p % 0.05, **p % 0.01.
(G) Quantification of CD8+ T cell memory subsets Tcm (CD62L+ CD127+), Tem (C
mean ± SD of 2 experiments with 3 mice per group per experiment; 2-WAY ANO
Representative gMFI values of respective groups indicated as a histogram inset
See also Figure S1.shows that miR-29 regulates the CD8+ T cell response to infec-
tion by establishing a gene regulatory program prior to infection,
which governs the developmental trajectory of T cells after infec-
tion. Our findings also raise the possibility that miRNAs can be
used as biomarkers for predicting vaccine efficacy and infection
outcomes at different stages of life.
RESULTS
miR-29 is required for normal CD8+ T cell function in
adult mice
Inmice and humans, adult naive CD8+ T cells express high levels
of miR-29, while naive neonatal cells express lower levels (Wis-
sink et al., 2015). Here, we examined the functional relevance
of adult miR-29 expression usingCre-mediated conditional dele-
tion of a floxed miR-29ab1 locus in gBT-I mice, which express a
TCR specific for the HSV-1 glycoprotein B498-505 epitope (Muel-
ler et al., 2002). We used PrimeFlow to examine miR-29 in naive
neonatal CD8+ T cells, and in adult cells with floxed miR-29ab1,
comparing littermates with and without Cre. As expected,
miR-29 levels are highest in adult cells with wild-type miR-29
(WT) and lowered upon miR-29ab1 excision (KO), mimicking
neonatal levels (Figure 1A). These differences in miR-29 levels
also exist in true naive (TN) and virtual memory (VM) subsets (Fig-
ure 1A). However, the presence of miR-29 in Cre+ adults, albeit
at lowered levels, implies incomplete excision of miR-29ab1,
which we confirmed using a PCR assay that indicated 45%–
75% excision (Figure S1A). We conclude that our mouse model
reduces miR-29 levels, approximating neonatal levels in adult
CD8+ T cells.
A characteristic difference between neonatal and adult CD8+
T cells is found within the naive pool; neonates contain a higher
proportion of VM cells and a smaller proportion of TN cells (Wang
et al., 2016). We examined the impact of reduced miR-29 levels
in adults and as expected, the pool was comprised predomi-
nantly of TN cells in control littermates (Cre-), whereas reduced
miR-29 depleted the TN proportion and elevated the VM popula-
tion (Figures 1B and S1B), a phenotype characteristic of neo-
nates (Wang et al., 2016; Smith et al., 2018). Reducing miR-29
increased expression of the transcription factors Tbet and
Eomes, which are expressed at higher levels in neonates (Smith
et al., 2014) and are predicted miR-29 targets (Wissink et al.,MFI) and histograms of miR-29a modal fluorescence intensities from bulk (top)
plenic naive CD8+ T cells and negative control (Neg; miR-29 probe omitted),
01; unpaired Student’s t test.
e. (Bottom) Histograms of Tbet and Eomes expression.
5-28 dpi) and LM-gB secondary infection. Data represent mean ± SD of 2 ex-
***p % 0.001, ****p % 0.0001.
at 7 dpi, with quantification (bottom), plottingmean ±SD of 2 experiments with
ells at 7 dpi.
dpi in spleen and liver homogenate, plotting mean ± SD of 2 experiments with 3
D62L- CD127+) and LLEC (KLRG1+ CD62L- CD43- CD27-) at 35 dpi, plotting
VA, ****p % 0.0001.
.





Figure 2. Loss of miR-29 lowers activation thresholds
(A) Kinetics of donor WT versus KO CD8+ T cell response from blood, with different ratios (indicated above plots) of LM-gB to WT LM, followed by secondary
infection with LM-gB. Data represent mean ± SD of 2 experiments with 6-7 mice per group per experiment; 2-WAY ANOVA, ***p % 0.001, ****p % 0.0001.
(B) Representative contour plots of WT versus KO effector cell populations at 7 dpi as described in panel (A).
(legend continued on next page)






OPEN ACCESS2015) (Figures 1B and S1B). These data imply roles for miR-29 in
adult CD8+ T cells and suggest that low levels of miR-29 in neo-
nates contribute to phenotypic differences between adult and
neonatal cells.
To investigate the significance of miR-29 expression in adult
CD8+ T cells, we performed adoptive single transfer experi-
ments, comparing cells harboring floxed miR-29 from Cre+ and
Cre- littermates (KO and WT, respectively) within congenically
marked recipients, which we infected with a gBT-I recombinant
vaccinia virus. Reduced miR-29 expression decreased the pri-
mary response somewhat and greatly impaired the memory
recall response following reinfection (Figure 1C).Whenwe exam-
ined the differentiation status of the effector pool at 7 days post-
infection (dpi) (Joshi et al., 2007), loss of miR-29 increased the
proportion of short-lived effector cells (SLECs) and reduced the
proportion of memory precursor effector cells (MPECs) (Figures
1D and S1C). This MPEC skew was pathogen independent,
observed inmultiple organs, and throughout theprimary andsec-
ondary responses (Figures 1D and S1C). Reduced miR-29 levels
led to elevated secretion of inflammatory cytokines at 7 dpi, after
gB peptide restimulation (Figure 1E), and after bystander activa-
tion (which is TCR independent; Kim and Shin, 2019) using IL-12
and IL-18 (Figure S1D).Moreover, loss ofmiR-29decreasedbac-
terial burden at the peak of the primary infection (Figure 1F) and,
perhapssurprisingly, alsoafter rechallenge infection (FigureS1E),
despite the smaller magnitude of the recall response (Figure 1C).
Increased pathogen clearance after reinfection may derive from
an earlier peak of expansion following reinfection (Figure 1C) or
possible changes in memory subsets. The changes caused by
reduced miR-29 levels persisted in secondary effector cells, as
seen by higher proportions of SLEC and pTem populations (Fig-
ure S1F). Furthermore, after rechallenge infection, loss of miR-29
resulted in downregulation ofCD62Landupregulation ofCXCR3,
twomarkers of activation, for both KLRG1+ and KLRG1- effector
subsets (Figure S1F). Thus, adult CD8+T cells deficient inmiR-29
resemble neonatal cells in terms of infection kinetics, rechallenge
phenotype, effector cell populations, and cytokine profiles (Smith
et al., 2014).
CD8+ T cells with high CX3CR1 levels typically differentiate
into T effector memory (Tem) cells, whereas those with low levels
are predisposed to become central memory (Tcm) cells (Gerlach
et al., 2016). Reduced miR-29 levels increased CX3CR1 expres-
sion during primary infection (Figure S1G). Thus, we examined
the memory repertoire at 35 dpi; CD8+ T cells with reduced
miR-29 had an increased propensity to form effector-like sub-
sets of memory T cells, including Tem and long-lived effector
cells (LLECs) (Jameson and Masopust, 2018), with a reduction
in long-lasting, tissue-specific and self-renewing memory cells
(Figures 1G and S1H). These data indicate that loss of miR-29
in adult cells promotes a faster acting, more-differentiated mem-
ory repertoire with reduced self-renewal capacities. These
altered proportions of memory cell subsets are reminiscent of
those in neonates (Zhang et al., 2014).(C) Dot plots of WT versus KO donor cell proportions at 5 days post DC immun
organs. Data represent mean ± SD of 2 experiments with 5-10 mice per group p
(D) Representative contour plots of WT versus KO effector cell populations at 5
See also Figure S2.Loss of miR-29 lowers activation thresholds
Wehypothesized thatmiR-29 controls the activation threshold of
naive cells. Thus, we used our conditional knockout model to
test how loss of miR-29 impacted activation in single transfer ex-
periments. We infected adult recipient mice with different ratios
of WT and gB recombinant Listeria monocytogenes (LM-gB),
and rechallenged with LM-gB. This strategy tested how loss of
miR-29 alters sensitivity to low and high stimulus, while maintain-
ing levels of inflammation. CD8+ T cells with reduced miR-29
required 10- to 100-fold less stimulus to enable expansion
throughout primary and secondary infections. However, under
conditions of highest stimulation, KO cells exhibited a reduced
response (Figure 2A). These results suggest that miR-29-defi-
cient cells require minimal stimulation to induce a robust
response yet are incapable of responding as effectively as WT
cells under conditions of high stimulation. To confirm these re-
sults, we performed in vitro antigen titration experiments, which
showed that miR-29-deficient cells proliferate faster than control
cells when stimulated with low levels of gB peptide or by TCR
stimulation (Figure S2A). Furthermore, miR-29-deficient cells
require minimal stimulus to differentiate into SLECs and form
few MPECs, regardless of the amount of stimulation during
both the expansion and memory phases (Figures 2B, S2B, and
S2C). This SLEC bias may derive from upregulation of Tbet
and Eomes (Figure S2D), which promote effector cell differentia-
tion (Jeker and Bluestone, 2013), and increased Blimp-1 (Fig-
ure S2E), which promotes SLEC formation (Rutishauser et al.,
2009; Welsh, 2009).
After investigating antigen strength, we asked whether miR-29
affects the activation threshold initiated via IL-12, a cytokine
important in CD8+ T cell differentiation (Joshi et al., 2007).
Following transfer of gB-specific donor cells with reduced or
normal levels of miR-29, we immunized recipient mice with den-
dritic cells loaded with gB peptide, and primed recipients with
varying amounts of IL-12. Across multiple organs, CD8+ T cells
with reduced miR-29 require minimal IL-12 stimulus to prolifer-
ate, but under high stimulus, their expansion plateaus at a lower
point than Cre- control cells (Figure 2C). These results are sup-
ported by in vitro IL-12 stimulation assays (Figure S2A).
Compared to their Cre- counterparts, the miR-29-deficient
(KO; Cre+) cells required less IL-12 to differentiate into SLECs
(Figures 2D and S2F), concomitant with dose-dependent upre-
gulation of Blimp-1, Tbet, and Eomes (Figures S2G and S2H).
These results suggest miR-29 helps establish normal activation
thresholds, by both antigen and cytokine stimulation. In contrast,
cells with less miR-29 exhibited a lower threshold, permitting
rapid proliferation and differentiation upon activation at the
expense of long-lived memory cell formation; phenotypes char-
acteristic of neonates (Smith et al., 2014).
Impact ofmiR-29 on the naiveCD8+ T cell transcriptome
CD8+ T cell naive populations are heterogeneous, and this
complexity relates to compartmentalization of effector andization with increased IL-12 priming versus negative PBS control in indicated
er experiment; 2-WAY ANOVA, *p % 0.05, ***p % 0.001, ****p % 0.0001.
days post DC immunization with IL-12 priming or PBS control.
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OPEN ACCESSmemory responses (Lee et al., 2013; Fink, 2013; van den Broek,
Borghans and van Wijk, 2018; Kaech and Cui., 2012). We used
single cell RNA-sequencing (scRNA-seq) to ask whether gene
expression programs across the naive subpopulations are
differentially impacted by miR-29. Using the 10x platform, we
performed scRNA-seq on naive cells isolated from adult
miR-29-deficient (Cre+; KO) andwild-type (Cre-;WT) littermates,
and also from wild-type neonates, profiling an average of 4,880
cells per sample, and detecting a median of 2,058 genes per
cell. There were 2,989 differentially expressed genes between
WT adult and neonatal CD8+ T cells (Figure S3A), and 457 genes
that differed between WT and KO adults (Figure S3B). Notably,
multiple genes that drive effector differentiation were upregu-
lated in the miR-29-deficient sample, including Eomes (Pearce
et al., 2003) and Cxcr3 (Kurachi et al., 2011), which are also ex-
pressed at high levels in neonates. UMAP (Uniform Manifold
Approximation and Projection) analysis suggested subtle differ-
ences between samples, with multiple distinct clusters common
to all samples (Figures 3A, 3B, and S3C). Nevertheless, the dis-
tribution of cells across clusters differed between samples (Fig-
ures 3C and S3D). When we examined the expression of miR-29
predicted targets, comparing each cluster individually between
miR-29-deficient andWT adults, we found that all major clusters
(96.7% of cells) exhibited significant loss of miR-29 regulation in
Cre+ transcriptomes (KO; Figures 3C and S3E). To characterize
the biological significance of the clusters, we examined estab-
lished CD8+ T cell markers (Figure 3D). Expression of VM
markers (Cd44 and Cd122) was highest in clusters 3 and 7,
and loss of miR-29 increased the proportion of cells within these
clusters (Figure 3C). These results support flow cytometry
analysis (Figure 1B), suggesting miR-29 promotes a TN fate.
Similarly, Eomes and Tbet (Tbx21), which drive effector differen-
tiation, were expressed highest in clusters 3 and 7. Collectively,
these results show that loss of miR-29 in adults alters the tran-
scriptome to promote neonatal-like features.
To investigate individual clusters, we performed enrichment
analysis on marker genes of each cluster using ImmGen Con-
sortium (IGC) gene sets, which describe expression signatures
delineating naive CD8+ T cell expansion into precursor effector
and subsequent memory cells (Best et al., 2013) (Figures 3E
and S3F). Clusters 2, 5, and 6, which exhibited a decrease in
cell proportions inmiR-29-deficient as compared to control adult
samples, were enriched for genes involved in late memory for-
mation and depleted for those driving effector formation.
Conversely, cluster 3, which was larger in the miR-29-deficient
sample, was enriched for gene sets associated with effector
cell function. These patterns were consistent when comparing
unclustered adult control samples to either miR-29-deficient or
neonatal samples (Figure S3G). These results suggest that loss
of miR-29 in adults led to fewer naive cells with the potential to
form long-lived memory cells. Finally, we examined enrichment
across the IGC gene sets for differentially expressed genes in
each cluster, comparing WT and KO adult transcriptomes
(Figures 3F and S3H). Consistently, across the major clusters
(1–5), loss of miR-29 led to an enrichment of gene sets involved
in effector differentiation, particularly in cluster 3, which con-
tained 2-fold more cells than the control sample. Conversely,
most major clusters in the adult control sample were enriched6 Cell Reports 37, 109969, November 9, 2021in gene sets associated with memory function (Figure 3F). These
analyses demonstrate heterogeneity within the naive CD8+ T cell
pool, and establish that miR-29 impacts the pool broadly, pri-
marily by regulating the proportion of naive cells predisposed
to differentiate toward memory or effector functions.
miR-29 reprograms naive neonatal CD8+ T cells to
improve memory response
Our data indicate that normal miR-29 expression is necessary for
CD8+ T cell memory functions in adults. Therefore, we asked
whether ectopic miR-29 is sufficient to reprogram neonatal cells
to mount an effective memory response. Current methods used
to introduce genetic material into primary naive CD8+ T cells
have major limitations: electroporation is inefficient and results
in high death rates; lentiviral transduction requires prior activa-
tion of cells; and chemical transfection is inefficient and inadver-
tently activates cells. We devised a method of increasing miRNA
levels in naive cells, based on delivery of RNAs to human and
mouse cancer cells using extracellular vesicles (EVs) purified
from human red blood cells as delivery vehicles (Usman et al.,
2018). After purification, we loaded EVs with miR-29 or negative
control (NC) miRNAmimics (Figure 4A) and confirmed delivery of
miR-29 to naive neonatal cells by RT-qPCR (Figure 4B). We note
that NC-loaded EVs had little impact on the naive cells, medi-
ating no change in TN and VM proportions (Figures 4C and S4A).
EV-mediated delivery of miR-29 to neonatal cells decreased
the proportion of VM cells (Figures 4C and S4A), and triggered
downregulation of Tbet and Eomes (Figures 4D and S4B), phe-
notypes typical of adult cells. This is consistent with analysis of
naive neonatal cells with natural variation in miR-29 levels (Fig-
ure S4C), demonstrating the robustness of EV-mediated delivery
of miR-29. To examine the impact of miR-29 on response to
infection, we performed adoptive transfers of neonatal cells
treated with EVs and observed a striking increase in memory
recall response after miR-29 delivery (Figure 4E). This change
in response to infection is notable given that we introduced
miR-29 in naive cells, with dilution of themimic upon proliferation
into effectors. While restimulated neonatal cells normally secrete
more pro-inflammatory cytokines at the peak of infection
compared to adult cells (Smith et al., 2014), production of
IFNg, GZMB and TNFa were decreased in response to miR-29
delivery to neonatal cells (Figures 4F and S4D). Consistent with
increased cytokine production, expression of Tbet and Eomes
at peak of infection was decreased (Figure S4E), transcription
factors that promote formation of SLECs over MPECs (Joshi
et al., 2007; Welsh, 2009). Indeed, the proportion of SLECs
was reduced in neonatal cells treated with miR-29 accompanied
by an increase in MPECs (Figures 4G and S4F). Thus, miR-29
overexpression in naive neonatal CD8+ T cells improves their
response to reinfection, likely by modulating the ratio of effector
cell types. Interestingly, this improvement persisted in the sur-
face phenotype of secondary effectors after rechallenge infec-
tion, as judged by the decreased proportion of SLECs and pre-
Tems, decreased CXCR3 expression, and increased CD62L
expression (Figure S4G).
We examined the effect of miR-29 delivery to naive neonatal
CD8+ T cells on the memory precursor populations generated






Figure 3. Analysis of naive transcriptomes by scRNA-seq
(A) scRNA-seq of WT and KO adult and neonatal (Neo) naive CD8+ T cells, visualized by UMAP.
(B) Individual UMAPs; as described in (A).
(C) Proportions of cells (y axis) for clusters (x axis; as identified in B); together with impact of miR-29 on predicted targets (x axis; p values denoted in legend).
(D) Expression of indicated genes (x axis), plotting percentage of cells expressing (denoted by circle size) and expression levels (color-coded) across clusters (y axis).
(E) Enrichment analysis for ImmGen gene sets (y axis) across clusters (x axis). Corrected p values denoted by circle size and color-coded (see legends).
(F) Enrichment analysis comparing WT and KO transcriptomes, for clusters 1 through 5; as described in (E).
See also Figure S3.












Figure 4. Induction of miR-29 in neonatal CD8+ T cells increases memory functions
(A) Experiment schematic.
(B) RT-qPCR quantification of miR-29a relative to U6 snRNA (y axis) from naive adult and EV-treated neonatal cells (x axis) delivering miR-29 or negative control
(NC) mimics; data represent mean ± SD of 3 independent experiments with 2 mice per experiment; 2-WAY ANOVA, *p % 0.05.
(C) Contour plots of TN and VM splenic CD8+ T cells from adult, neonate and EV-treated neonatal cells.
(D) Histograms of modal Tbet and Eomes expression from splenic naive cells.
(E) Kinetics of blood-derived donor cell proportion (y axis) through VACV-gB primary (5-28 dpi) and LM-gB secondary infections (x axis). Data represent mean ±
SD of 2 independent experiments with 8-10 mice per group per experiment; 2-WAY ANOVA, *p % 0.05, **p % 0.01, ***p % 0.001, ****p % 0.0001.
(F) Histograms of modal cytokine expression after gB peptide restimulation of splenic donor CD8+ T cells at 7 dpi.
(legend continued on next page)






OPEN ACCESSinfection. Delivery of miR-29 decreased CX3CR1 expression,
with an increase in precursor Tcm cells (preTcm) and decrease
in precursor Tem cells (preTem) (Figures 4H and S4H). Moreover,
at 35 dpi, we observed a decrease in both Tem and LLECs when
cells were treated with miR-29 and an increase in Tcm and Trm
proportions (Figures 4I and S4I). These results demonstrate that
increasing miR-29 levels in naive neonatal CD8+ T cells is suffi-
cient to form persistent, resident, canonical memory cells,
approximating attributes of adult CD8+ T cells.
Impact of miR-29 on gene regulation in naive cells
AlthoughmiR-29 induction in naive neonatalCD8+T cells led to an
increased propensity to form memory cells, the identities of the
underlying regulatory pathways were unclear. We performed
RNA-seq to investigate changes in gene expression that result
upon EV-mediated delivery of miR-29 to naive neonatal CD8+
T cells. Because of the extensive differences between TN and
VM cells, we performed RNA-seq separately on each class of
naive cell, including also naive cells from adults. Principal compo-
nent analysis (PCA) revealed that PC1 correlated well with TN
versus VM, as expected (Figure 5A). Notably, PC3 correlated
with the adult-neonatal axis, and transcriptomes from neonatal
cells treated with miR-29 moved toward adult transcriptomes,
for both TN and VM samples but more pronounced in VM cells.
PC2 and PC4, which were similar in scale to PC3, weremore diffi-
cult to interpret (Figures S5A and S5B). Next, we performed
enrichment analysis using the IGC gene sets (Figure 5B). In gen-
eral, these analyses indicated that naive neonatal cells treated
with miR-29 lose enrichment in multiple gene sets associated
with effector status and are no longer depleted in memory gene
sets. These changes were more evident for the VM cell compari-
sons. Taken together, these data indicate that raising levels of
miR-29 in naive neonatal cells is sufficient to alter the transcrip-
tome, inducing expression patterns more similar to adult cells.
To extend our analysis of regulatory changes induced by miR-
29, we performed ATAC-seq on the same set of samples
analyzed by RNA-seq, which allowed us to assess whether alter-
ations tomiR-29 levels in naive cells were sufficient to reprogram
the chromatin landscape. PCA, using peaks detected by ATAC-
seq as features, demonstrated clear partitioning of the different
samples (Figure 5C). In contrast with the RNA-seq analysis,
PC1 suggested an adult-neonatal axis, with PC2 suggesting
the VM-TN axis. As before, exposure to miR-29 induced global
changes, causing neonatal samples to resemble those of adults
(Figure 5C). We performed enrichment analysis using IGC gene
sets on the genes proximal to differentially accessible peaks,
compared between control and miR-29-induced neonatal sam-
ples. Across multiple gene sets, genes close to peaks more
accessible in miR-29-treated samples exhibited more adult-
like signatures than the control neonatal samples (Figure S5C).(G) Quantification of SLEC (left) and MPEC (right) at 7 dpi from indicated sample
pendent experiments with 6-7 mice per group per experiment. Otherwise as des
(H) Representative contour plots of pre-memory cell subsets across groups bas
(I) Bar graph quantification of CD8+ T cell memory subsets (x axis) Tcm (CD62L+ C
donor cells at 35 dpi. Data represent mean ± SD of 2 independent experiments
Representative gMFI values of respective groups indicated as a histogram inset
See also Figure S4.To examine these changes in chromatin accessibility systemat-
ically, we performed k-means clustering (k = 6) on the ATAC-seq
peaks, and then associated the peaks to the closest annotated
gene. Next, we performed enrichment analysis on the clusters
using the IGC gene sets (Figure 5D). There is a pronounced trend
of miR-29-treated neonatal samples behaving as an intermedi-
ate between control neonatal and adult samples (Figure 5D, bot-
tom). For example, cluster 4 contains ATAC-seq signatures that
are highest for neonatal and lowest for adult samples, with inter-
mediary signal from the miR-29-treated neonatal samples. This
analysis indicated that cluster 4 is associated with effector
gene sets, implying loss of accessible chromatin for such genes
in response to miR-29. Cluster 1 also showed enrichment of
effector gene sets, and the corresponding ATAC-seq signal is
highest in the VM control neonatal samples and reduced in
response to miR-29. Conversely, cluster 2 shows a depletion
of effector gene sets, and the corresponding signal is highest
in the adult samples and least accessible in neonates, with
increased signal in the miR-29-treated neonatal samples.
Thus, the chromatin landscape of naive neonatal CD8+ T cells
loses signal at effector gene loci and gains signals at memory
gene loci in response to miR-29; in both regards, these changes
result in a landscape mimicking that of adult naive CD8+ T cells.
We next looked for enrichment of transcription factor (TF)
binding motifs in the differently accessible chromatin regions.
Runx-family-, Eomes-, and Tbet (Tbx21)-TF motifs are enriched
in neonatal open chromatin regions, as expected for TFs
involved in effector differentiation (Kaech and Cui, 2012; Best
et al., 2013; Chen et al., 2018); miR-29 treatment reduced the
extent of these enrichments. Similarly, motifs corresponding to
the Foxo family and Pou/f family (Oct1/2), which are expressed
in cells adopting an activated effector state (Hedrick et al.,
2012; Shakya et al., 2011), were also most pronounced in
neonatal samples, and elevatedmiR-29 reduced this enrichment
(Figures 5E, 5F, S5D, S5E, S5F, and S5G; Table S1). KLF2, KLF4
and Sp1 motifs are enriched in adult but not neonatal samples;
these factors contribute to maintenance of a nonproliferative
state characteristic of adult naive CD8+ T cells (Weinreich
et al., 2009; Yamada et al., 2009; Moskowitz et al., 2017). This
suggests that TFs which restrain proliferation of adult naive cells
are depleted in neonatal cells, lowering the proliferation
threshold upon stimulation.
To examine TF binding induced bymiR-29more rigorously, we
performed BaGFoot analysis, which identifies valleys or foot-
prints caused by TF binding within accessible regions (Baek,
Goldstein and Hager, 2017). This approach distinguishes be-
tween potentially active elements (accessible chromatin) from
those that are implicated as active (footprinted). In VM cells,
Eomes and Tbet (Tbx21) motifs are enriched in control neonatal
cells compared to counterparts treated with miR-29; similars based on KLRG1 versus CD127/IL7R. Data represent mean ± SD of 2 inde-
cribed in (E).
ed on CD27 (y axis) and CX3CR1 (x axis) expression at 5 dpi.
D127+), Tem (CD62L- CD127+) and LLEC (KLRG1+ CD62L- CD43- CD27-) of
with 4-5 mice per group per experiment. Otherwise as described in (E).
.








Figure 5. miR-29-mediated control of gene expression programs in CD8+ T cells
(A) PCA of RNA-seq from naive CD8+ T cells from adults and EV-treated neonates.
(B) Enrichment analysis with ImmGen gene sets on differentially expressed genes comparing EV-treated (NC versus miR-29) neonatal cells, for VM (left) and TN
(right) transcriptomes. Circle sizes denote corrected p values, with enrichment and depletion color-coded (see legend).
(C) PCA of ATAC-seq from naive CD8+ T cells from adults and EV-treated neonates.
(D) Clustering of ATAC-seq peaks (bottom), and enrichment analyses per cluster (as described in B, top).
(E and F) Enrichment analyses of transcription factor (TF) binding motifs in differentially accessible chromatin regions, using ATAC-seq datasets from neonatal
cells treated with control-EVs (Neo+NC), compared with indicated samples (x axis), plotting adjusted p values (color-coded, see inset legend) for motifs enriched
in all four comparisons. Motifs with p values % 10320 plotted as 10320.
(legend continued on next page)






OPEN ACCESSresults were observed for Runx1 and AP-1 family members Fos
and Jun, factors critical in the response to TCR stimulation (Jain
et al., 1992) (Figures 5G and 5H; Table S2). Similar results were
observed when comparing adult and neonatal samples (Figures
S5H and S5I; Table S2). Interestingly, Bach, Smad and GATA
motifs showed enrichment in control neonatal samples, which
was diminished upon miR-29 treatment (Figures 5G, 5H, S5H,
and S5I; Table S2); these TFs regulate effector states and differ-
entiation in helper T cells (Richer, Lang and Butler, 2016; Malho-
tra and Kang., 2013; Lentjes et al., 2016). Overall, these analyses
imply that differences in TF binding between adult and neonates
can be partially recapitulated in neonatal cells by treating with
miR-29.
Adjusting miR-29 levels in human CD8+ T cells
In human cells, miR-29 is also differentially expressed in an age-
dependent manner (Wissink et al., 2015) (Figure S6A). We used
our EV-delivery system to inhibit miR-29 in adult cells and sup-
plement levels in umbilical cord blood-derived cells, in order to
ask whether the age-dependent functions of miR-29 in mice
exist also in humans (Figure 6A). MiR-29 levels were decreased
significantly in naive human adult CD8+ T cells upon delivery of
miR-29 inhibitor (ASO) (Figure 6B), resulting in upregulation of
miR-29 targets (Figures 6C, S6B, and S6C). Similarly, miR-29
levels were modestly increased after delivery of miR-29 mimics
to cord-derived naive cells (Figure 6D), resulting in more repres-
sion of miR-29 targets in response to increased, but still physio-
logical, levels of miR-29 (Figures 6C, S6B, and S6C). Importantly,
EV treatment alone did not significantly affect initial naive pheno-
types after the 5-day EV incubation (Figure S6D).
Inhibition of miR-29 in naive adult cells was sufficient to in-
crease expression of the activation markers CD69, CD25 and
CD44, levels of effector cytokines, and proliferation (Figures
6E, S6E, and S6F). Thus, miR-29 modulation in human naive
adult cells reprograms fundamental attributes of CD8+ T cells,
resulting in a more cytotoxic state typical of newborns (Kwoczek
et al., 2018; Jacks et al., 2018). Conversely, when we delivered
miR-29 to naive human cord cells, levels of activation markers
and effector cytokines were decreased, along with a reduction
in proliferation (Figures 6F, S6E, and S6F). These results demon-
strate that addition of miR-29 to human cord cells is sufficient to
induce phenotypes characteristic of adults.
MiR-29-mediated gene regulation in human CD8+
T cells
To determine how miR-29 impacts gene regulation in human
CD8+ T cells, we performed RNA-seq using naive human
CD8+ T cells, in which we age-adjusted miR-29 levels using
EVs. PCA showed a pronounced separation between adult and
cord blood samples (PC1), with a clear difference between
adults with and without miR-29 inhibition (PC3) and less pro-
nounced differences between the two cord sample sets (Fig-
ure 7A). We note that PC2 appeared to reflect a batch effect(G and H) Bag plots analyzing footprints of TF motifs, compared between Neo
accessibility (x axis), and footprint depth (y axis).
See also Figure S5 and Tables S1–S2.and/or variation in expression between individuals (Figure S7A).
We observed significant changes in expression of the miR-29
targets TBX21 (Tbet) and EOMES, both as a function of age
and upon modulation of miR-29 (Figure 7B). In addition, expres-
sion of many other effector genes changed upon miR-29 modu-
lation, including PRDM1 (Blimp-1), CXCR3 and CX3CR1
(Figure 7B).
To examine these changes more generally, we performed
enrichment analysis using the IGC gene sets. Comparing the
adult- and cord-derived transcriptomes from the control sam-
ples revealed that the cord-derived cells are enriched in gene
sets associated with effector functions (Figure S7B). We next
compared enrichments between the two sets of adult samples;
inhibition of miR-29 increased enrichment of genes associated
with cell cycling and division, and depleted genes associated
with memory precursor status (Figure 7C). Comparisons be-
tween the two sets of cord-derived samples revealed that addi-
tion of miR-29 decreased enrichment in effector gene sets. Thus,
in both humans and mice, age-adjusting miR-29 levels in naive
cells alters the transcriptome extensively, driving long-lasting
changes in downstream differentiated cells, and modulating
the speed, strength, and longevity of response to infection.DISCUSSION
Here, we establish a role formiR-29 in licensing adult CD8+T cells
towardmemory fates, a conclusion supported bymultiple lines of
evidence. First, miR-29-deficient adult mice are unable to mount
effective memory recall responses. We deleted the miR-29a/b-1
locus in only the ab T cell lineage, an important consideration as
miR-29has roles in hematopoieticprogenitors and in non-immune
lineages (Hilz et al., 2017; Mehta and Baltimore, 2016; Kriegel
et al., 2012; Kwon et al., 2019). Second, miR-29 overexpression
in naive neonatal mouse cells promotes adult-like phenotypes,
increasing MPEC proportions and improving recall response.
Finally, age-adjusting miR-29 levels in human or mouse naive
CD8+ cells impacts gene expression programs; adult cells with
reduced miR-29 levels show increased activity of genes associ-
ated with effector fates concomitant with a reduced activity of
memory formation. Similarly, addition of miR-29 to naive neonatal
cells is sufficient to bias expression programs toward those
of adults. Thus, high miR-29 expression in adult CD8+ T cells
is necessary for effective memory cell formation, and raising
miR-29 levels in naive neonatal cells is sufficient to improve their
memory response. Neonatal CD4+ T cells also express low levels
ofmiR-29 (Yuetal., 2016) and fail to formmemorycells (Zenset al.,
2017); thus, our findings may also explain age-related differences
in the CD4+ T cell response.
Age-related differences in T cell development in the thymus
and fetal liver have been linked to regulation by Lin28 and the
let-7 miRNA family, which is repressed by Lin28 (Pobezinsky
et al., 2015; Yuan et al., 2012). These studies establish that in ne-
onates, high levels of Lin28 and low let-7 program hematopoietic+miR-29 and Neo+NC samples for VM (G) and TN (H) cells. Plotting flanking






Figure 6. Reprogramming human CD8+ T cells by age-adjusting miR-29 levels
(A) Experiment schematic.
(B) RT-qPCR quantification of miR-29a (y axis) from naive adult cells treated with EVs loaded with miR-29 inhibitor (ASO) relative to negative control ASO (NC).
Data represent mean ± SD of 3 independent experiments with 2-3 samples per experiment.
(C) Histograms ofmodal Tbet and Eomes expression, after EV-treatments of cord cells treatedwithmiR-29 (mimic) or control (NC) oligonucleotides and adult cells
treated with miR-29 inhibitor (ASO) or control (NC) oligonucleotides.
(D) RT-qPCR quantification of miR-29a (y axis) from naive cord cells treated with EVs loaded with miR-29 mimic relative to negative control mimic (NC). Data
represent mean ± SD of 3 independent experiments with 2-3 samples per experiment.
(E) Histograms of flow measurements of activation markers, cytokines and CFSE (proliferation) from stimulated adult cells treated with EVs loaded with control
(blue) ormiR-29 ASO (red) or negative control (gray; no brefeldin A ormonensin treatment). (Bottom right) Scatterplot of proliferation indices. Data represent mean
± SD of 2 experiments with 2-3 samples per experiment; unpaired Student’s t test, **p % 0.01.
(F) Histograms, as described in (E), for cord-blood derived cells treated with EVs loaded with miR-29 (green) or negative control (orange) mimics. ***p % 0.001.
Representative gMFI values of respective groups indicated as a histogram inset.
See also Figure S6.
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OPEN ACCESSstem cells and thymocytes to bias naive neonatal CD8+ T cells
toward a VM phenotype, which is mediated, at least in part, by
control of PLZF and IL-15. Thus, like miR-29, let-7 levels also
contribute to establishing differences between the naive cells
of adults and neonates, driving contrasting responses to infec-12 Cell Reports 37, 109969, November 9, 2021tion. These results highlight the potential relationship between
miR-29 and let-7/Lin-28, although it is unclear whether they are
functioning in independent gene regulatory pathways, or
whether both are key regulators in a unified pathway. Our data












ASO ASO mimic mimic
Adult Cord
Figure 7. Human adult and cord CD8+ T cells can be transformed through manipulating the level of miR-29
(A) Principal component analysis of gene expression profiles for adult NC ASO, adult miR-29 ASO, cord NC ASO and cord miR-29 mimic samples, showing
principal components 1 and 3.
(B) Expression of five genes relative to NC samples. Gene expression in adult NC and miR-29 ASO samples were normalized to mean expression of genes in the
adult NC samples. Gene expression in cord NC andmiR-29mimic samples were normalized to mean expression of genes in the cord NC samples. p values were
calculated by differential expression analysis; EdgeR, ****p % 0.0001, **p % 0.01, *p % 0.05
(C) Enrichment analysis for ImmGen gene sets on differentially expressed genes between adult NC and miR-29 ASO (left), cord NC and miR-29 mimic (right).
Circle sizes denote corrected p values, with enrichment and depletion color coded (see legend).
See also Figure S7.
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OPEN ACCESSregulatory determinant, serving to modulate effector and mem-
ory responses, but how miR-29 affects let-7 regulation in pro-
genitor cells remains unclear.
What is the teleological benefit of miR-29-mediated control of
age-related differences in the CD8+ T cell response to infection?Our theory is that miR-29 levels control the activation ‘set-point’
in naive cells during different stages of life. In neonates, lowmiR-
29 expression decreases the activation threshold, permitting a
rapid proliferative response. While an enhanced capacity to pro-
liferate may help neonates compensate for fewer CD8+ T cells,Cell Reports 37, 109969, November 9, 2021 13
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OPEN ACCESSthe vigorous primary response comes at the expense of memory
formation. Still, rapid protection may be advantageous during
early stages of development, as immunological memory is unim-
portant if the host fails to survive. As the host ages and the naive
T cell repertoire diversifies, increasing miR-29 expression raises
the activation threshold, enabling a balanced response and
retention of cells in the memory pool. Thus, miR-29 may act as
a developmental switch, adjusting CD8+ T cell activation thresh-
olds during different stages of life based upon the relative need
to mount a rapid effector response versus generating long-lived
memory cells.
Although miR-29 functions at multiple points during T cell
development and after activation (Zhang and Bevan, 2010; Bro-
nevetsky et al., 2013; Liston et al., 2012; Podshivalova and Sal-
omon, 2013), a major point of consequential miR-29 activity is
within naive cells. The long-lasting impact of miR-29 is
conferred, at least in part, by changes in the chromatin land-
scapemade in naive cells, which later impact downstream differ-
entiation decisions. Presumably, certain enhancers whose
accessibility is controlled by the miR-29 regulatory program
only contribute to expression differences as naive CD8+ T cells
activate and differentiate. This role for a miRNA, specifying cell
fates before activation, expands upon the current dogma that
miRNA regulation maintains the naive pool and also shapes the
T cell response after activation (Wells, Pobezinskaya and Pobe-
zinsky, 2020).
Currently, the field has proposed several models of T cell dif-
ferentiation, including the ‘decreasing potential hypothesis’
(Kaech and Cui, 2012), but our data support the ‘developmental
programming pathway’ model, whereby differently aged CD8+
T cells are programmed in the naive state. Our work suggests
that miR-29 sculpts the regulatory program by targeting certain
genes directly, in particular Tbet and Eomes, but many changes
in gene expression, including Cx3cr1, Cxcr3, Blimp-1, CD44,
and IL2rb, are downstream of these direct targets. Indeed, the
extensive changes to the chromatin landscape documents the
regulatory cascade initiated by miR-29. These alternatively pro-
grammed naive regulatory landscapes alter activation thresh-
olds of CD8+ T cells, dictating their sensitivity toward antigenic
and cytokine stimuli, thereby defining downstream effector
states and memory cell lineages.
Methods to effectively manipulate CD8+ T cells while main-
taining a naive state have been lacking. Viral transduction and
transient delivery methods suffer from inefficient delivery and/
or inadvertent cell activation. In addition, genetic approaches
in mice are challenging for essential genes or those with pleio-
tropic phenotypes. We used extracellular vesicles (EVs) loaded
in vitro to deliver miRNAs or miRNA inhibitors to naive primary
human and mouse CD8+ T cells (Usman et al., 2018). Manipula-
tion of miR-29 levels to alter memory cell differentiation may
prove useful in vaccine design, autoimmunity treatment, and
cancer therapeutics (Rupaimoole and Slack, 2017). Ultimately,
the approach may have therapeutic applications (György et al.,
2015), with potential relevance to engineered T cells, given that
EVs can be loaded with a variety of biomolecules not limited to
small RNAs.
Our work is notable for its potential to identify biomarkers that
can predict vaccine success and infection outcomes in neo-14 Cell Reports 37, 109969, November 9, 2021nates. For example, relative miR-29 expression could provide
an informative readout for the proportion of adult and young
derived cells present at various stages of life, thus predicting
the likelihood that a vaccine would result in generation of mem-
ory. Moreover, if baseline miR-29 expression predicts outcome,
then more favorable vaccine outcomes could be achieved by
manipulating miR-29 expression prior to immune challenge.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Excel Microsoft N/A
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Seurat v3.2.2 Stuart et al., 2019 https://satijalab.org/seurat/index.html
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Morpheus Broad Institute https://software.broadinstitute.org/
morpheus/
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BaGFoot v0.9.7.2 Baek, Goldstein, and Hager, 2017 https://sourceforge.net/projects/bagfootr/
bamCoverage v3.4.3 in deepTools Ramı́rez et al., 2016 https://deeptools.readthedocs.io/en/
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bigWigMerge, bedGraphToBigWig UCSC toolkit http://hgdownload.soe.ucsc.edu/admin/
exe/
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hisat2 v2.2.0 Kim et al., 2019 http://daehwankimlab.github.io/hisat2/
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Materials availability
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Data and code availability
d RNA-seq, ATAC-seq and single cell RNA-seq data have been deposited at GEO and are publicly available as of the date of
publication. Accession numbers are listed in the key resources table. All data reported in this paper will be shared by the
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d All original code has been deposited at Zenodo and is publicly available as of the date of publication. DOIs are listed in the key
resources table.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.EXPERIMENTAL MODEL AND SUBJECT DETAILS
Biological samples
Human T cells
Frozen de-identified whole male adult (18-55 years of age) peripheral blood mononuclear cell samples and frozen deidentified male
cord blood (39-41 weeks gestation) mononuclear cell samples were obtained from the University of Rochester Pediatric Processing
Biorepository Core at the University of Rochester in accordancewith University of Rochester’s Committee on the Use of Human Sub-
jects for Research as all samples were deidentified, and the research involved interaction with the donors in the NICU or voluntary
donation.
Mice
C57Bl6, B6-Ly5.2/Cr mice were purchased from the National Cancer Institute colony, and B6-Thy1.1/CyJ CD4-Cre mice, B6/CyJ
TCRa/mice and Thy1.1 B6.PL-Thy1a /CyJmice were purchased from the Jackson Laboratory. MiR-29ab-1 fl/fl mice were gener-
ously provided by Dr. Stefan Costinean of Ohio State University and crossed to the B6-CyJ CD4-Cre mice. All mouse strains were
crossed with gBT-I TCR homozygous transgenic mice (transgenic for TCRab specific for the HSV-1 glycoprotein gB498–505 peptide
SSIEFARL) provided by Dr. Janko Nikolich-Zugich (University of Arizona, Tucson, AZ). All mice were sex matched as males at
8-12 weeks of age for adult group and 5-7 days old for neonate group and maintained under pathogen-free conditions at Cornell
University’s College of Veterinary Medicine. The experiments in this study were performed in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and protocols reviewed and
approved by the Institutional Animal Care and Use Committee at Cornell University.
Cell culture
B16-Flt3 mouse melanoma tumor cell line was provided by Dr. Stephen Jameson (University of Minnesota, MN) (Fulton et al., 2015).
Cells were cultured in RP-10 (RPMI supplemented with 10% FBS) and passaged twice before experimental use. Conditioned media




Tissue distribution and vascular staining
For acquiring samples in the memory phase after infection, 3 mg of CD8b FITC in 100 ml PBS was injected intravenously into the
retro-orbital sinus and left in circulation for 3 minutes before the animal is euthanized. For vascular stained memory and peak of
infection samples, blood samples were obtained by retro-orbital bleed using a glass pipette. Mice were then euthanized and
spleen, lymph nodes (cervical, mesenteric and inguinal), and lung or liver were removed. Single cells suspensions of spleen,
and lymph node were made by manual dissociation and filtration through a 40 mm filter. Liver tissue was dissociated automatically
using C tubes on a gentleMacs Dissociator (Miltenyi), then filtered through a 70 mm filter and hepatocytes removed by 3 slow cen-
trifugal spins to further enrich for lymphocytes. Lung tissue was homogenized and digested using C tubes on a gentleMacs Dis-
sociator with 0.5 mg/mL collagenase and 0.02 mg/mL DNase I in RP-10 for 30 minutes at 37C followed by filtration through a
70 mm filter and ACK Lysis Buffer incubation to remove RBCs and enrich for lymphocytes. Following preparation of single cell
suspensions, cells were stained directly or positively enriched for CD8s using CD8a microbeads then processed for flow
cytometry.
Flow cytometry
All antibodies were purchased from Thermo Fisher Scientific or Biolegend. When fixation was required, the IC fixation and perme-
abilization kit from Thermo Fisher Scientific was used according to manufacturer’s instructions. For intracellular staining, the BD
FoxP3 fix/ permbuffer set was used. Flow cytofluorimetric data were acquired on an Attunewith 4 lasers and a customBDSymphony
instrument equipped with five lasers using the DiVa software. Analysis was performed using the FlowJo software.
Adoptive single transfer experiments
Splenocytes were collected from congenically marked male adult and male neonate C57Bl6/Thy1.1 gBT-I CD45.2 mice and incu-
bated with CD8a microbeads. Cells were then passed over an LS magnetic column, according to the manufacturer’s instructions
and CD8+ T cells were isolated via positive magnetic selection (90%–95% purity). 1x104 CD4Cre ± miR-29fl/fl gBT-I (KO/WT) or
neonate CD8-enriched splenocytes from male donor mice were adoptively transferred (i.v.) into 10-12-week-old adult male B6-
Ly5.2 CD45.1 recipient mice the day before infection. At indicated days post-infection, the proportion and phenotype of the donor
cells in the blood were determined by flow cytometry.
Infections
Unless stated otherwise, mice were infected with Recombinant vaccinia virus expressing the gB-peptide, designated VACV-gB that
was generously provided by Dr. S.S. Tevethia (Pennsylvania State University, College of Medicine). Mice were infected with 2x105
PFU of VACV-gB (i.p.). For specific experiments, Listeria monocytogenes colonies were selected for growth in liquid culture and bac-
teria were grown to log phase. Mice were intravenously infected with 5x103 CFU of either wild-type Listeria monocytogenes (strain
10403, obtained from Dr. Nikolich-Zugich, designated WT-LM), or a recombinant strain of Listeria monocytogenes expressing the
gB-peptide (obtained from Dr. Sing Sing Way, designated LM-gB).
Dendritic cell IL-12 immunization
Adult male 8-10-week-old C57/Bl6 mice were subcutaneously injected with 5x106 B16-Flt3 L cells after 2 cell culture passages. After
10-14 days, when skin tumors were visible, tumor mice were given LPS i.v (2 mg/mouse) to mature dendritic cells. The next day
spleens were harvested and manually homogenized and run through a 40 mm filter. The spleen homogenate was resuspended in
complete RPMI media containing rGM-CSF (50 ng/mL) with B16-Flt3L conditioned media in a 2:1 ratio, respectively with 1 mMSSIE-
FARL (gB) peptide for 5 hours at 37C with constant gentle agitation. After the incubation period, dendritic cells were purified with
CD11c microbeads using positive magnetic selection (95% purity), according to the manufacturer’s instructions. The isolated
CD11c+ dendritic cells were counted, washed and 1x106 gB loaded dendritic cells were injected i.v. into recipient B6-Ly5.2 mice
for stimulation of Cre+/ miR-29 fl/fl gBT-I donor CD8+ T cells (KO/WT), which were adoptively transferred into CD45.1 recipient
mice 24 hours prior. 24 hours after DC immunization, mice were injectedwith IL-12 i.p. (200 ng, 20 ng, 2 ng) or PBS for 4 days consec-
utively. Donor cells were assessed on day 5 after IL-12 priming.
PrimeFlow RNA Assay
Adult/neonatal mouse and human adult/cord male CD8+ T cells were enriched frommouse spleen homogenate and adult peripheral/
cord bloodmononuclear cells, respectively, via CD8amicrobead positivemagnetic selection. Purified CD8+ T cells were labeled with
surface antibodies then fixed and permeabilized according to manufacturer’s specifications as initial sample preparation. Cells were
then incubated with customized Type 1 A647 miR-29a probe set or customized Type 1 internal positive control RPL13A probe set to
achieve target hybridization. Signal amplification was achieved by further hybridization of preamplifier and amplifier DNA to target
probe then fluorescently labeled probes were added for detection via flow cytometry. All steps followed by manufacturer’s specifi-




20,000 CD8+ T cells enriched from spleen of Cre+ and Cre- miR-29 fl/fl gB+ (KO and WT respectively) male mice were singly trans-
ferred to male adult TCRaKO mice by i.v. injection. TCRaKO recipient mice were infected with 5x104 cfu LM-gB i.v. within 24 hours
then reinfected with 5x104 cfu LM-gB i.v. 4 weeks later. 3 days after primary and secondary infection, spleen and liver were har-
vested, weighed and homogenized using the gentleMACS Dissociator in lysis solution (sterile deionized water with 0.02% NP-40
substitute). Spleen and liver homogenates were then serially diluted in sterile deionized water from 10-2 to 10-8 and 10 ml plated
on strep BHI plates in quadruplet. BHI plates were then allowed to dry and incubated at room temperature for 3 days. Colonies
were then enumerated using a counter manually by 2 lab personnel once visible and bacterial titer was calculated.
In vitro mouse proliferation assay
Spleens were harvested from male Cre+ and Cre- miR-29 fl/fl gBT-I mice (KO and WT) and filtered through a 40 mm filter to prepare
single-cell suspensions. CD8+ T cells were purified using CD8amicrobeads according to the manufacturer’s protocol. The isolated
CD8+ T cells were resuspended in PBS and labeled with CFSE at a 1:500 dilution. Cells were resuspended in media containing exog-
enous hIL-2 (2 ng/mL) and stimulated with either cognate peptide (SSIEFARL) (106 M and 109 M) in a 96-well round-bottom plate or
plate-bound mouse anti-CD3ε (0.1 or 10 mg/mL) + soluble anti-CD28 (0.5 or 10 mg/mL) in a 96-well flat-bottom plate or plate-bound
mouse anti-CD3ε (2 mg/mL) + soluble anti-CD28 (5 mg/mL) with IL-12 (0.2 or 20 ng/mL).
In vitro mouse gB peptide restimulation
Bulk splenocytes from infected mice at peak of infection were restimulated in vitro with 107 M gB peptide for 4 hours at 37C in the
presence of 3 mg/mL of Brefeldin A. Cells were then fixed and stainedwith both surface and intracellular antibodies for flow cytometric
analysis of cytokine secretion.
In vitro mouse bystander activation
CD8+ T cells from Cre+ (KO) and Cre- (WT) miR-29 fl/fl gBT-I mice were isolated by positive magnetic selection using anti-CD8a
microbeads according to manufacturer’s instructions. Following isolation, cells were incubated in RP-10 with IL-2 alone (2 ng/mL)
or IL-2 (2 ng/mL), IL-12 (20 ng/mL) and IL-18 (20 ng/mL) for 18 hours. After 18 hours, 3 mg/mL Brefeldin A was added to the cells
and incubated for an additional 4 hours. Cells were then harvested, fixed and stained with both surface and intracellular antibodies
for flow cytometry analysis of cytokine secretion.
PCR analysis of floxed miR-29ab1 locus
Genomic DNA was extracted from Cre+ (KO) and Cre- (WT) TN and VM nuclei using the QIAamp Fast DNA Tissue Kit (QIAGEN),
following the manufacturer’s protocol. 50 ng of genomic DNA was diluted 1:5 twice. PCR was performed using ExTaq polymerase
(Takara Bio), following the manufacturer’s protocol, with the forward primer 50-TGTAAGCCTCGTGCTCACTG-30 and the reverse
primer 50-ACCGTCAAATCTGCAACCCA-30. Approximate percent excision was calculated using densitometry analysis of band in-
tensity with Image Lab v6.0.1 (Bio-Rad Laboratories).
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from naive CD8+ T cells using TRIzol following the manufacturer’s instructions. For qRT-PCR of miR-29a
and miR-29b, RT was performed using the miRCURY LNA RT Kit (QIAGEN), with 50-100 ng of total RNA as input and 1 attomole of
cel-miR-39-3p from the miRCURY LNA Spike-In Kit (QIAGEN) spiked in, per the manufacturer’s protocol. cDNA was diluted 1:50 in
the qPCR reaction using the miRCURY LNA SYBR Green PCR Kit (QIAGEN) following the manufacturer’s protocol, denatured at
95C for 2 min followed by 45 cycles of 95C for 10 s and 56C for 1 min on a LightCycler 480 (Roche). Forward and reverse
primers for hsa-miR-29a-3p (YP00204698), hsa-miR-29b-3p (YP00204679), hsa/mmu U6 snRNA (YP00203907) and cel-miR-
39-3p (YP00203952) were designed by QIAGEN. Data were normalized to the spike-in cel-miR-39-3p and housekeeping gene
U6 snRNA, and analyzed by the 2-DDCT method. For reverse transcription of miR-29 target mRNA genes, 150-250 ng of total
RNA was incubated with 5 mg of dN9s (IDT) in a 12.5 mL reaction volume at 80C for 5 min, followed by 60C for 5 min. Then,
4 mL of RevertAid 5x Reaction Buffer (Thermo Scientific), 0.5 mL of RiboLock (Thermo Scientific), 2 mL of 10 mM dNTPs and
1 mL of RevertAid Reverse Transcriptase (Thermo Scientific) were added, and the reaction was incubated at 42C for 1 hour,
70C for 10 minutes and held at 4C. For qPCR, the cDNA was diluted 1:50 and performed using SYBR Green master mix
(Life Technologies) on a LightCycler 480 (Roche) by denaturing at 95C for 2 min followed by 40 cycles of 95C for 15 s, 59C
for 25 s and 72C for 30 s. For qPCR primers, see Table S3. Data were normalized to the housekeeping gene PPIA and analyzed
by the 2-DDCT method.
RNA oligonucleotide sequences and modifications
The ssRNA miR-29a ASOs (50-AUCGUGGUAGACUUUAGCCAAU-30) and negative control ASOs (50-AUUUUUAGCGCAC
CUAAUUAC-30) were synthesized with 20-O-methyl modifications at every ribonucleotide by Sigma-Aldrich (USA). The dsRNA
miR-29 mimics (guide strand: 50-UAGCACCAUCUGAAAUCGGUUA-30) (passenger strand: 30-ACCGAUUUCAGAUGGUGUGA
AU-50) and negative control mimics (guide strand: 50-UAAAAAUCGCGUGGAUUAAUG-30) (passenger strand: 30-UUAAUUUACGCGCell Reports 37, 109969, November 9, 2021 e6
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room temperature in 1x siRNA buffer (Dharmacon).
Human RBC EV generation, purification and characterization
One pint of Group O- blood was obtained from New York Blood Center from a healthy male donor less than 30 years old with no
communicable diseases and CMV negative in New York region with informed consent and consent to the standard disease panel
testing. All experiments with human blood samples were performed according to the guidelines and the approval of Cornell University
Human Subjects Ethics committee. Whole blood was depleted of white blood cells using a leukoreduction filter (Haemonetics, USA)
then allowed to rest for 2weeks at 4Cwith gentle agitation every 48 hours. RBCswere then separated fromplasma by centrifugation.
Isolated RBCs were diluted in RBC storage buffer (sterile filtered PBS with citric acid, sodium citrate, glucose, adenine, sodium chlo-
ride, mannitol and sodium hydrogen phosphate) and treated with 10 mM calcium ionophore overnight. To purify EVs, RBCs and cell
debris were removed by three rounds of centrifugation at 600g-3,260g at 4C. The remaining supernatant were vacuum filtered
through a 0.45 mm pore membrane filter (Millipore). EVs were concentrated by using ultracentrifugation with a SW32Ti rotor (Beck-
man Coulter, USA) at 100,000g for 70 min at 4C. EVs were resuspended in cold PB then layered above 5 mL 60% sucrose cushion
(frozen at 80C) and centrifuged at 100,000g for 16 h at 4C using a SW32Ti rotor (Beckman Coulter) with reduced braking speed.
The red layer of EVs was collected and washed once with cold PBS using ultracentrifugation in a SW32Ti rotor (Beckman Coulter) at
100,000g for 70 min at 4C. All ultracentrifugation experiments were performed with a Beckman XE-90 ultracentrifuge (Beckman
Coulter). Purified RBCEVs were resuspended in 3 mL PBS, aliquoted and stored at 80C. The concentration and size distribution
of EVs were quantified via dilution using a NanoSight Tracking Analysis NS300 system (Malvern, UK) provided by the Cornell
Nanoscale Science and Technology Facility.
RBC-EV chemical transfection
Transfection of RBCEVs were performed using the Exofect Exosome Transfection kit (System BioSciences, USA). PBS, 10 mM oligo
material (miR-29 ASO/NC ASO/miR-29 mimic/NCmimic), 2.5 mL Exofect solution and 25 mg RBCEVs were mixed to a final volume of
200 mL per well and incubated at 37C with gentle shaking for 15 minutes. The RBCEV transfection solution was immediately trans-
ferred onto ice for 30 minutes. PBS was then added and samples were centrifuged for 30 min at 14,000g at 4C in a table top fixed
rotor centrifuge (Eppendorf) twice. Final pellet was resuspended in 100 mL of EV-free complete RPMI-1640 media with 10% FBS,
Pen/Strep and L-glutamine per well.
In vitro EV nucleic acid treatment of naive mouse and human T cells
200,000 human or mouse magnetically enriched CD8+ T cells were plated in RPMI-1640 complete media with 10% FBS, Pen/Strep
and L-glut with IL-7 (2 ng/mL) at a concentration of 2x106 cells/mL as described below. 100 mL of RBCEV transfected media was
added to each well and mixed well to break up any cell-EV aggregates. Cell and EV mixture was incubated at 37C for 4-5 days
and media was changed every 48 hours.
In vitro human TCR stim, proliferation and cytokine secretion assay
Frozende-identifiedwholemale adult (18-55 years of age) peripheral bloodmononuclear cell samples and frozendeidentifiedmale cord
blood (39-41 weeks gestation) mononuclear cell samples were obtained from the University of Rochester Pediatric Processing Bio-
repository Core at the University of Rochester in accordance with University of Rochester’s Committee on the Use of Human Subjects
for Research as all samples were deidentified, and the research involved interaction with the donors in the NICU or voluntary donation.
The frozencordbloodderivedmononuclear cells andadult peripheral bloodmononuclear cellswerequick thawed,washedand rested in
RPMI-1640 complete media for 12-16 hours. Human CD8+ T cells were isolated using positive magnetic selection by incubating with
humanCD8amicrobeads. Cells were then passed over an LSmagnetic column, according to themanufacturer’s instructions and incu-
batedwitholigo loadedEVsaspreviouslydescribedabove.After 5-dayoligo-EV incubation, the isolatedhumanCD8+TcellswereFACS
sorted to acquire a 95% pure naive CD8+ cell population (CD45RA+, CD45RO–, CD27+, Viability lo). Sorted naive CD8+ T cells were
resuspended in PBS and labeled with CFSE Proliferation Dye according to manufacturer specifications. Cells were then resuspended
in media containing exogenous hIL-2 (2 ng/mL) and incubated with human biotin CD2, CD3 and CD28 beads from the T cell Activa-
tion/Expansion Kit (Miltenyi) according tomanufacturer’s instruction for 3 days. Completemedia with IL-2 was changed every 48 hours.
OnDay 4, CD8+ T cells were resuspended in RPMI-1640 completemedia containing 2 mg/mL PHA-L for 2 hours then incubated with 1x
monensin and 3 mg/mL brefeldin-A for 4 additional hours. Three replicates of adult and three replicates of cord sampleswere used in the
in vitroexperiment.Cellswere thenharvested,fixedandstainedwithbothsurfaceand intracellular antibodies for flowcytometryanalysis.
Mouse single cell RNA sequencing
Adult or neonatal mouse spleens were isolated in complete media and CD8+ T cells were positively selected for using magnetic mi-
crobead (Miltenyi) selection according tomanufacturer’s instructions. Splenic cells were then prepped for bulk naive CD8 FACS sort-
ing on the SONY by staining with CD8, CD4 and Viability Dye (97% purity) and 60,000 CD8+ cells sorted into PBS + 0.04% BSA.
Sorted cells were then counted on a TC20 to capture 8,000 viable CD8+ T cells. Single cell 30 RNA sequencing libraries were prepared
by the Genomics core at Cornell University using a 10x Genomics Chromium instrument and the Chromium Single Cell 30 Reagent kite7 Cell Reports 37, 109969, November 9, 2021
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58 bp insert read lengths.
Human CD8+ sorting for RNA-seq
Adult or cord PBMCs were isolated in complete media and CD8+ T cells were positively selected for using magnetic microbead (Mil-
tenyi) selection according to manufacturer’s instructions. Cells were then prepped for naive CD8 subset FACS sorting on the SONY
by staining with CD8, CD4, CD27, CD45RA and CD45RO and Viability Dye (97% purity) and 100,000 CD8+ cells sorted into PBS +
2% BSA + 2 mM EDTA.
Mouse CD8+ sorting for RNA-seq and ATAC-seq
Adult or neonatal spleens were isolated in complete media and CD8+ T cells were positively selected for using magnetic microbead
(Miltenyi) selection according to manufacturer’s instructions. Cells were then prepped for naive CD8 subset FACS sorting on the
SONY by staining with CD8, CD4, CD44 and CD122 and Viability Dye (97% purity) and 200,000+ CD8+ cells sorted into PBS +
2% BSA + 2 mM EDTA.
Human/mouse RNA preparation and RNA sequencing
20,000 FACS sorted cells were placed in Trizol and RNA was extracted according to manufacturer’s instructions, with the addition of
a chloroform extraction, Glycoblue (ThermoFisher) carrier prior to precipitation (1 hour at 4C), and a second wash of the pelleted
RNA in 70% ethanol. RNA integrity was confirmed on a Fragment Analyzer (AATI). Libraries were prepared by the TREx core at Cor-
nell University as follows: RNA-seq libraries were generated with the non-directional NEBNext Ultra II RNA Library Prep Kit (New En-
gland Biolabs) using total RNA isolated from 20,000 cells at 10 ng/mL. All RNA-seq libraries were sequenced with 85 nt single-end
reads on a NextSeq500 (Illumina).
Mouse ATAC-seq nuclei prep, library preparation and sequencing
FACS sorted cells were permeabilized in lysis buffer (10mMTris-Cl pH 8.0, 300mMsucrose, 10mMNaCl, 2mMMgAc2, 6mMCaCl2,
0.2%NP-40 (Igepal), 0.5 mMDTT, 1x Pierce protease inhibitor (Thermo Scientific), and 40 units of RiboLock RNase inhibitor (Thermo
Scientific) per 10mLbuffer) by brief aggressive pipetting, washedwith bufferW (10mMTris-Cl pH 8.0, 300mMsucrose, 10mMNaCl,
2 mMMgAc2, 0.008% Tween20, 0.5 mM DTT, 1x protease inhibitor, and 40 units of RiboLock RNase inhibitor per 10 mL buffer), and
resuspended in storage buffer (50 mM Tris-Cl pH 8.3, 40% glycerol, 5 mMMgCl2, 0.1 mM EDTA, 0.5 mM DTT, 1x protease inhibitor,
and 40 units of RiboLock RNase inhibitor per 10 mL buffer). The cells were pelleted at 1000g for 8 minutes for each step of buffer
change. The permeabilized cells were counted, snap-frozen in liquid nitrogen, and stored at 80C. Libraries were prepared by
the TREx core at Cornell University from 25,000 permeabilized cells as described in Buenrostro et al. (2015) and Corces et al.
(2017). Briefly, frozen permeabilized cells were thawed, washed twice in ATAC-RSB buffer containing 0.1% Tween20, resuspended
in Transposition Mix (Nextera DNA Sample Preparation Kit, Illumina) containing 0.1% Tween20 and PBS, and incubated for
30 minutes at 37Cwith shaking (1000 rpm). After column cleanup, libraries were amplified using Nextera PCR oligos (Nextera Index
Kit, Illumina) and Ultra II Q5 Master Mix (NEB) for a total of 12-14 PCR cycles based on qPCR quantification after the initial 5 cycles.
The libraries were cleaned up twice (in series) with a 2:1 ratio of SPRIselect beads (Beckman Coulter). ATAC-seq libraries were
sequenced with 75 nt single-end reads on a NextSeq500 (Illumina).
Single Cell RNA-seq analysis
Preprocessing
Fastqs were aligned to the mouse transcriptome (mm10) for each sample type using cellranger count in Cell Ranger pipelines (10x
Genomics, v3.1.0). Cellranger aggr was then used to aggregate the multiple sample types with default parameters.
Data analysis
Data normalization, cell clustering, and differential expression were carried out using the Seurat R package v3.2.2 (Stuart et al., 2019).
Cells with fewer than 200 genes or more than 15% of mitochondria genes were excluded from the analysis. Genes detected in fewer
than 3 cells were also excluded from the analysis.
Integration was performed with Harmony R package (Korsunsky et al., 2019) and SCTransform (Hafemeister and Satija, 2019) in
Seurat, respectively.
In Harmony integration, read counts were normalized using the Seurat NormalizeData function. Variable features used to down-
stream analysis were identified using the Seurat FindVariableFeatures function (nfeatures = 2000). Data was then scaled and
centered using ScaleData function in Seurat. PCA was performed using the Seurat RunPCA function. Harmony integration was
performed using RunHarmony function in Harmony R package. Uniform Manifold Approximation and Projection (UMAP) and
Graph-based clustering (using the Seurat FindNeighbors and FindClusters functions) were performed with the top 20 principal com-
ponents at the resolution of 0.5.
SCTransformwas performed on cells of each sample type separately. SelectIntegrationFeatures was used to select features to use
for integration (nfeatures = 3000). PrepSCTIntegration, FindIntegrationAnchors and IntegrateData were performed to integrate the
data. Read counts were normalized using the Seurat NormalizeData function. PCA was performed using the Seurat RunPCA func-Cell Reports 37, 109969, November 9, 2021 e8
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of 0.3 with the top 20 principal components.
miRNA targeting signature
miRNA targets were defined as expressed genes (mean normalized read counts across cells > 0.01) with at least one target site for
the particular miRNAwith context++ score%0.2 in TargetScan (version 7.2) (Agarwal et al., 2015). The background set consisted of
genes with at least one target sites of other conserved miRNAs, excluding all potential targets to the miRNA being tested. For cells in
each identified cluster, log2 fold changes between WT and KO samples were calculated for miRNA targets and background genes
separately. Distribution of log fold changes of the two groups of genes are compared using Wilcoxon test.
Marker genes
Marker genes for each cluster were identified using FindAllMarkers function in Seurat. Marker genes are genes that are identified to
be expressed higher in the tested cluster than all other clusters. Normalized data matrix in RNA assay was used in differential expres-
sion testing. Genes detected in at least 10% of cells in the tested cluster or all other clusters are included, without requirements for
fold differences between samples (logfc.threshold = 0). Only positive markers are returned. Default parameters were used unless
described otherwise.
Differential expression
Differentially expressed genes are identified using FindMarkers function in Seurat. Genes detected in at least 10% of cells in either of
the two populations are included, without requirements for fold differences between samples (logfc.threshold = 0).
For differential expression between samples, genes with adjusted p values smaller than 0.05 are classified as the differentially ex-
pressed genes. For differential expression within each cluster, genes with logFC greater than 0.05 are classified as the differentially
expressed genes.
Gene set analysis
ImmGen clusters from Best et al. (2013) were used as gene sets for the gene set analysis. The pool of genes was the intersect of
marker genes in all groups (when analyzing marker genes for each cluster), all genes included for differential expression (when
analyzing differentially expressed genes between sample types) and genes in ImmGen gene sets. Two-sided Fisher exact test
was used to test that whether the groups of genes were enriched with the ImmGen gene sets. P values from gene set enrichment
tests on each group of genes were FDR-corrected.
ATAC-seq analysis
ATAC-seq read processing and peak calling
Raw sequencing reads were processed using ENCODE ATAC-seq pipeline (v1.1.7). Trimmed adaptor sequences were ‘R1:
CTGTCTCTTATACACATCT; R2: CTGTCTCTTATACACATCT’. Reads were mapped to the mouse genome (mm10). Paired-end
mode was enabled and peak calling was performed using MACS2 v2.1.1.20160309 with ‘-f BEDPE’ (https://github.com/taoliu/
MACS) (Zhang et al., 2008). Irreproducibility Discovery Rate (IDR) v2.0.3 (Li et al., 2011) (https://github.com/nboley/idr, https://
github.com/kundajelab/idr) analysis was enabled for cross-validation to compare replicates. Default parameters were used unless
described otherwise. Reads were counted on each peak for all samples with featureCounts v2.0.0 (-p -F SAF -s 0 -Q 38) (Liao, Smyth
and Shi, 2014).
Principle Component Analysis (PCA)
Peaks with mean Counts Per Million (CPM) across samples > = 1 are kept. Counts are transformed to log2 scale with rlog function in
DESeq2 v1.26.0 (Love, Huber and Anders, 2014). PCA is performed using prcomp function in R.
Differential Accessibility
Read counts were normalized to CPM. Peaks with CPM > 1 in at least one sample were kept. Peaks with significantly more reads in
one condition compared to another (FDR < 0.05) was identified using EdgeR v3.28.1(McCarthy, Chen and Smyth, 2012; Robinson,
McCarthy and Smyth, 2010).
Clustering
Read counts are normalized toCPMand peakswithmeanCPMacross samples > = 1 are kept. Means of read counts for each sample
type were taken across replicates. Counts were converted to z-scores across sample types (rowwise z-scores) prior to clustering
analysis. Morpheus (Broad Institute) was used for k-means (k = 6) clustering and visualization by heatmaps.
Peak annotation
AnnotatePeaks.pl in HOMER (Heinz et al., 2010) was used to assign each peak to a nearest gene based on the shortest distance
between the peak and gene’s RefSeq transcription start site (TSS) in the mouse genome (mm10).e9 Cell Reports 37, 109969, November 9, 2021
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ImmGen clusters from (Best et al., 2013) were used as gene sets for the gene set analysis. The pool of genes was the intersect of
genes associated with peaks included when identifying differentially accessible peaks (for analyzing genes associated with differen-
tially accessible peaks), or genes associated with peaks in all six clusters (for analyzing genes associated with each cluster) and
genes in all ImmGen gene sets. Two-sided Fisher exact test was used to test that whether the groups of genes were enriched
with the ImmGen gene sets. P values from gene set enrichment tests on each group of genes were FDR-corrected.
Transcription factor motifs
Transcription factor binding profiles are obtained for from JASPAR (Fornes et al., 2020) CORE database v2020 (Vertebrates), with 746
non-redundant TF motifs.
Motif enrichment for transcription factor binding sites
Analysis of Motif Enrichment (AME) (McLeay and Bailey, 2010) in MEME Suite was used to identify motifs enriched in sequences of
peaks more accessible in one condition relative to control sequences. Default parameters were used unless described otherwise.
Control sequences were obtained from randomly subsetted insignificant peaks using fasta-subsample in MEME Suite (Bailey
et al., 2009), and the number of subsetted control peaks was the mean of the numbers of significant peaks in both directions.
Transcription factor footprint identification
BaGFoot (Baek et al., 2017) was used to identify transcription factor activity. Prior to BaGFoot analysis, bam files of replicates were
merged for each sample type.
Visualization
Bam files were normalized to RPKM using bamCoverage (v3.4.3, -bs 1) in deepTools (Ramı́rez et al., 2016). BigWig files for replicates
of every sample type are merged using bigWigMerge (v2) and then sorted and converted to back bigwig format using bedGraphTo-
BigWig in UCSC toolkit. Bigwig files are visualized using UCSC genome browser.
RNA-seq analysis
RNA-seq reads processing
Adaptors were trimmed from raw reads with trim_galore with default parameters (Babraham Bioinformatics: https://www.
bioinformatics.babraham.ac.uk/projects/trim_galore/). Reads were mapped to the hg38 or mm10 genome with hisat2 v2.2.0 (Kim
et al., 2019). FeatureCounts v2.0.0 (Liao, Smyth and Shi, 2014) was then used to counts mapped reads for genomic features using
GENCODE human gene annotation v30 ormouse gene annotation v21 (-s 0 -Q 50). Peaks withmeanCounts PerMillion (CPM) across
samples > = 1 are kept. Counts were transformed to log2 scale with rlog function in DESeq2 v1.26.0 (Love, Huber and Anders, 2014).
PCA was performed using prcomp function in R.
Differential expression and gene set analysis
Raw counts were normalized to CPM values, and genes with CPM > 1 in at least one sample were kept for differential expression
analysis. EdgeR v3.28.1(McCarthy, Chen and Smyth, 2012; Robinson, McCarthy and Smyth, 2010) was used to identify differentially
expressed genes using likelihood ratio test.
Genes with p values smaller than 0.05 in differential expression analysis were classified as differentially expressed genes used in
gene set analysis.
Human genes are first converted to their mouse homologs using Vertebrate Homolog data fromMouse Genome Informatics (MGI)
(URL: http://www.informatics.jax.org/homology.shtml). ImmGen gene sets from (Best et al., 2013) were the gene sets used for the
gene set analysis. The pool of genes was the intersect of all genes included for differential expression and genes in ImmGen gene
sets. Two-sided Fisher exact test was used to test that whether the groups of genes were enriched with the ImmGen gene sets.
P values from gene set enrichment tests on each group of genes were FDR-corrected.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis for flow cytometric data was performed using Prism 7 software (GraphPad). Error bars represent SD unless other-
wise noted. The exact value of ‘n’ represents the sample size as biological replicates with respect to the number of mice or the num-
ber of human donors, as denoted in the figure legend. Significance was determined by unpaired t test, or one-way or two-way
ANOVA, followed by multiple comparisons posttest, as indicated in the figure legends. Significance is denoted as follows: *p %
0.5 and **p % 0.01 ***p % 0.001 and ****p % 0.0001.Cell Reports 37, 109969, November 9, 2021 e10
